Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Cilta-cel: a paradigm shift in the treatment of multiple myeloma

Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, comments on the approval of the chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel) in multiple myeloma. Studies have reported response rates (RRs) reaching 90%, with a duration of response (DOR) of approximately 12-18 months. This drug represents an alternative for heavily pre-treated patients who have become refractory to other available anti-myeloma therapies. Ongoing research is currently evaluating this therapy in earlier lines of treatment and whether it could replace hematopoietic stem cell transplantation (HSCT). In parallel, ongoing studies are also exploring strategies to improve the persistence of CAR-Ts. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.